2019 CYIR Finalized

20 3. Individuals with sarcoidosis who need treatment around diag- nosis have a two-fold increased risk of death and therefore represent a more vulnerable group. 4. Unfortunately, due to the lack of clinical patient information the authors were not able to investigate mortality by disease phe- notype or correlate their medication-based proxy for severity with other disease severity indices. 5. Future studies are important to investigate mortality in sarcoid- osis in well-defined patient subgroups with different disease phenotypes; early identification of those at increased risk might help improve their outcome. PULMONARY HYPERTENSION IN SARCOIDOSIS Baughman RP, Shlobin OA, Wells AU, Alhamad EH, Culver DA, Barney J, Cordova FC, Carmona EM, Scholand MB, Wijsenbeek M, Ganesh S, Birring SS, Kouranos V, O’Hare L, Baran JM, Cal JG, Lower EE, Engel PJ, Nathan SD. Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry. Respir Med 2018; 139: 72-78. Summary This article describes the results of a multi-national registry of patients with sarcoidosis associated pulmonary hyper- tension (ReSAPH). A total of 176 patients with pulmonary artery wedge pressure (PAWP) of 15 mmHg or less and a mean pulmonary artery pressure (mPAP) ≥ 25 Hg were analyzed. Data collected included hemodynamics, forced vital capacity (FVC), diffusion capacity of carbon monoxide (DLCO), chest x-ray, and 6-min walk distance (6MWD). There was a significant correlation between DLCO percent predicted (% pred) and mPAP (Rho = −0.228, p = 0.0068) and pulmonary vascular resistance (PVR) (Rho = −0.362, p < 0.0001). PVR was significantly higher in stage 4 disease as in stage 0 or 1 disease (p < 0.05 for both comparisons). About two-thirds of the SAPH patients came from the United States (U.S.). There was a significant difference in the rate of treatment between U.S. (67.5%) versus non-U.S. (86%) (Chi Square 11.26, p = 0.0008) sites. The authors concluded that the clinical features of SAPH were similar across multiple centers in the U.S., Europe, and the Middle East. The severity of SAPH was related to reduced DLCO. Comments 1. This multinational effort provides a interesting global perspec- tive and insight into features of SAPH. 2. The study was however not designed to determine the preva- lence of SAPH within any individual clinic. 3. Important was the absence of correlation between any of the spirometric values and severity of PH. 4. The results suggest that presence of fibrosis is not essential for the development of SAPH and attests to the multi- factorial nature of its etiology. 5. SAPH patients in the U.S. were less likely to receive treatment for their PH than their European counterparts. INFLIXIMAB BIOSIMILAR INFLECTRA® IN SARCOIDOSIS Schimmelpennink MC, Vorselaars ADM, van Beek FT, Crommelin HA, Deneer VHM, Keijsers RGM, Veltkamp M. Efficacy and safety of infliximab biosimilar Inflectra® in severe sarcoidosis. Respir Med 2018; 138S :S7-S13. Summary The article describes real-world data on the use of inflix- imab biosimilar Inflectra®, a monoclonal antibody against tumor necrosis factor alpha (TNF-α) as third-line therapy in severe sarcoidosis. In this retrospective cohort study from the Netherlands, 29 patients treated with Inflectra®, were analyzed. Patients received Inflectra® intravenously monthly at a dose of 5 mg/kg. Trough levels were measured before every infusion. Before and after 6 months of induc- tion therapy pulmonary function and disease activity were evaluated using Standardized Uptake Value (SUV) of the 18F-fluorodeoxyglucose by positron emission tomography (18F-FDG PET), soluble interleukin-2 receptor (sIL-2R), angiotensin converting enzyme (ACE) and health-related quality of life (HRQOL). In patients with pulmonary sarcoid- osis as main treatment indication (n = 15) the predicted FVC improved with 8.1%, p < 0.05. Furthermore, in the whole group HRQoL improved significantly (p < 0.001), whereas SUVmax and sIL-2R significantly reduced (p < 0.001 and p = 0.001 respectively). Hospitalization due to infections occurred in four patients. None of the patients discontinued Inflectra® due to side effects. Furthermore, all patients had detectable trough levels indicating development of neutral- izing antibodies. Comments 1. Infliximab biosimilar Inflectra® appears to have similar efficacy and safety profile in the treatment of sarcoidosis compared to Remicade®. 2. Inflectra® can therefore be considered a less expensive alter- native for patients with refractory disease. 3. Mean +8.1% change in FVC outweighs the improvement of 2.5% found by Baughman et al. in AJRCCM 2006;174(7):795- 802. 4. Although the study design has the possibility of recall bias, data presented is the only evidence available so far on the use of Inflectra® in sarcoidosis. 5. Data are in line with results of NOR-SWITCH trial [Jorgensen et al. Lancet 2017;389(10086);2304-16]. T-HELPER 17.1 CELLS IN SARCOIDOSIS Broos CE, Koth LL, van Nimwegen M, In ‘t Veen JCCM, Paulissen SMJ, van Hamburg JP, Annema JT, Heller-Baan R, Kleinjan A, Hoogsteden HC, Wijsenbeek MS, Hendriks RW, van den Blink B, Kool M. Increased T-helper 17.1 cells in sarcoidosis mediastinal lymph nodes. Eur Respir J 2018; 51(3): pii:1701124. SARCOIDOSIS

RkJQdWJsaXNoZXIy MTM1ODMw